Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Trial Details

NCT ID
NCT06819215
Phase
PHASE1 / PHASE2
Sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • VB15010
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Age ≥ 18 at the time of screening;
  • Histological or cytological confirmation of advanced malignancy ;
  • Progressive cancer at the time of study entry;
  • Adequate organ and marrow function as defined by the protocol;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →